CLL or small lymphocytic lymphoma
Haematology · 2023–2023
1decision
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| zanubrutinib Treatment of previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients inappropriate for fludarabine-based… | Mar 2023 | Recommended | 1 individuals Haematology Society · Rare Cancers Australia · Lymphoma Australia · Leukaemia Foundation |
Who spoke
Haematology Society · Rare Cancers Australia · Lymphoma Australia · Leukaemia Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.